Novel Oral Agent for ESR1-Mutated Breast Cancer Boosts PFS in Second-Line

(MedPage Today) — CHICAGO — The investigational oral agent vepdegestrant more than doubled median progression-free survival (PFS) versus fulvestrant (Faslodex) in previously treated estrogen receptor (ER)-positive metastatic breast cancer patients…

Source link : https://www.medpagetoday.com/meetingcoverage/asco/115827

Author :

Publish date : 2025-05-31 12:00:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
						1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30

Novel Oral Agent for ESR1-Mutated Breast Cancer Boosts PFS in Second-Line

The Covid Inquiry Podcast: ‘I wasn’t the decision maker’

Sacituzumab or Chemo in First-Line TNBC: Which Is Better?

Related Posts

Adding Neoadjuvant Nivolumab to Chemo Improved Survival in Resectable NSCLC

Private ispace Resilience probe will attempt lunar landing this week

Selumetinib Shrinks NF1-Plexiform Neurofibromas in Adults, Too

All International Travelers Should Get Measles Vaccinations, CDC Says

Parenting Training Reduces Healthcare Needs for Kids With Asthma Plus ADHD

AKT Combination Increased PFS in Metastatic HR-Positive/HER2-Negative Breast Cancer

Adding Neoadjuvant Nivolumab to Chemo Improved Survival in Resectable NSCLC

Private ispace Resilience probe will attempt lunar landing this week

Selumetinib Shrinks NF1-Plexiform Neurofibromas in Adults, Too

All International Travelers Should Get Measles Vaccinations, CDC Says

Parenting Training Reduces Healthcare Needs for Kids With Asthma Plus ADHD

AKT Combination Increased PFS in Metastatic HR-Positive/HER2-Negative Breast Cancer

Do Pregnant Women Need COVID Boosters?

FDA Approves Moderna’s New COVID Vaccine With Restricted Use

Categories

Archives